Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 July 2021Website:
http://www.staterabiopharma.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 19 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
STAB Latest News
23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. LION/POLARIS LUX 4 S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ACCORINVEST GROUP S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ILIAD S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
7TH October 2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. SAMMONTANA ITALIA S.p.A.
02/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. CMA CGM Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated [01/10/2024]] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
[17.09.2024] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [AZELIS FINANCE NV] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated [11.09.2024] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
[31/07/2024] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [Crown European Holdings S.A] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated [30/07/2024] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
[12/7/24] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [RINO MASTROTTO GROUP S.P.A] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated 11/7/2014 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
What type of business is Statera Biopharma?
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. operates as a subsidiary of Biostax Corp.
What sector is Statera Biopharma in?
Statera Biopharma is in the Healthcare sector
What industry is Statera Biopharma in?
Statera Biopharma is in the Biotechnology industry
What country is Statera Biopharma from?
Statera Biopharma is headquartered in United States
When did Statera Biopharma go public?
Statera Biopharma initial public offering (IPO) was on 28 July 2021
What is Statera Biopharma website?
https://www.staterabiopharma.com
Is Statera Biopharma in the S&P 500?
No, Statera Biopharma is not included in the S&P 500 index
Is Statera Biopharma in the NASDAQ 100?
No, Statera Biopharma is not included in the NASDAQ 100 index
Is Statera Biopharma in the Dow Jones?
No, Statera Biopharma is not included in the Dow Jones index
When was Statera Biopharma the previous earnings report?
No data
When does Statera Biopharma earnings report?
The next expected earnings date for Statera Biopharma is 29 November 2024